Investigators from the National Institute for Occupational Safety and Health within the US Centers for Disease Control and Prevention and the Occupational Safety and Health Administration emphasized that there is a risk of Zika exposure for those working in the lab setting. The agencies received reports of three Zika virus exposure incidents related to occupational exposure in a lab setting during the period of heightened disease transmission around the world.
Research shows that Zika virus has circulated at a low but sustained level for at least 16 years, suggesting that Zika virus can adapt to persistent endemic transmission. Health systems need to adapt to cope with regular occurrences of the severe complications associated with infection.
The clinical outcomes associated with Zika virus (ZIKV) in the Americas have been well documented, but other aspects of the pandemic, such as attack rates and risk factors, are poorly understood.
As several Zika virus vaccine candidates undergo clinical trials, a group of investigators is taking an alternate approach to quell transmission by genetically engineering mosquitoes to be resistant to the virus.
Researchers identified space-time clusters of dengue, chikungunya, and Zika, to understand the dynamics and interaction between these simultaneously circulating arboviruses in a densely populated and heterogeneous city.
Thousands of Zika virus cases went unreported in Cuba in 2017, according to an analysis of data on travelers to the Caribbean island. Veiling them may have led to many other cases that year.
The Nebraska scientists used two forms of weakened Adenovirus to serve as vectors to deliver the Zika vaccine.
No drugs are currently available to treat Ebola, Dengue, or Zika viruses. Scientists have now identified key ways the three viruses hijack the body's cells, and they found at least one potential drug that can disrupt this process in human cells.
Researchers at the University of Hawaii medical school have successfully developed a vaccine candidate for the Zika virus, showing that it is effective in protecting both mice and monkeys from the infection.
Researchers have generated six Zika virus antibodies that could be used to test for and possibly treat a mosquito-borne disease that has infected more than 1.5 million people worldwide.